Regencell Bioscience Leads Pharma Stocks in Year-to-Date Performance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 22 2025
0mins
Source: SeekingAlpha
S&P Healthcare Index Performance: The S&P healthcare index (XLV) achieved a year-to-date increase of 12.2% by mid-December 2025, ranking as the sixth-highest performing sector among the S&P 500 indexes.
Top Pharmaceutical Stocks: Regencell Bioscience (RGC) led the pharmaceutical sector with an extraordinary YTD performance of +15,138.46%, followed by Terns Pharmaceuticals (TERN) and Nuvation Bio (NUVB), which both received strong buy ratings.
Notable Stock Ratings: Nuvation Bio (NUVB) and Liquidia (LQDA) were highlighted for their strong buy ratings of 4.99 and 4.90, respectively, indicating strong investment potential.
Healthcare ETFs: Various healthcare ETFs, including XLV, VHT, and IHI, were mentioned as options for investors looking to gain exposure to the healthcare sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGC
About RGC
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regencell Securities Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, that they must apply to be lead plaintiff by June 23, 2026, to participate in the class action and seek compensation.
- Transparent Fee Structure: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, minimizing financial burdens for participants.
- Firm's Track Record: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its extensive experience and success in this legal domain.
- Case Background: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to significant financial risks and potential regulatory scrutiny, which could adversely affect the company's reputation and financial health.
See More
Regencell Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Regencell in the U.S. District Court for Maryland on behalf of investors who purchased securities between October 28, 2024, and October 31, 2025, indicating significant legal risks for the company.
- Allegations of Misrepresentation: The lawsuit alleges that Regencell made false and misleading statements regarding its business and compliance policies, exposing investors to substantial financial risks and potential regulatory scrutiny.
- Investor Rights Protection: Investors have until June 23, 2026, to apply to be lead plaintiffs in the lawsuit, highlighting the importance of protecting investor rights and potentially influencing future investment decisions.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in shareholder rights, securities, and commercial litigation, underscoring its expertise and influence in safeguarding investor interests.
See More
Regencell Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against Regencell in the U.S. District Court for Maryland on behalf of investors who purchased securities between October 28, 2024, and October 31, 2025, indicating significant legal risks for the company.
- Allegations of Misrepresentation: The lawsuit alleges that Regencell made false and misleading statements regarding its business operations and compliance policies, exposing investors to substantial financial risks and potential regulatory scrutiny.
- Investor Rights Protection: Investors have until June 23, 2026, to apply to be lead plaintiffs, highlighting the importance of protecting investor rights and the potential impact on future investment decisions.
- Legal Consultation Offered: Bragar Eagel & Squire offers free consultations and encourages affected investors to contact attorneys directly to ensure they understand their legal rights and possible remedies.
See More
Regencell Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply as lead plaintiffs by June 23, 2026, to participate in the class action, as those who do not will be ineligible for compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, thereby alleviating financial burdens on investors seeking justice.
- Legal Risks Exposed: The lawsuit alleges that Regencell failed to disclose risks of market manipulation during the class period, exposing investors to significant financial risks and subjecting the company to regulatory scrutiny and potential legal liabilities, which could have long-term reputational impacts.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and experience in handling similar cases.
See More
Faruqi & Faruqi Encourages Regencell Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Regencell Bioscience Holdings Limited related to securities purchased between October 28, 2024, and October 31, 2025, indicating possible legal risks for the company.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing phone numbers and extension for discussing their legal rights, demonstrating a commitment to investor advocacy.
- Class Action Deadline: The firm reminds investors of the June 23, 2026 deadline to seek lead plaintiff status in a federal securities class action filed against Regencell, highlighting the urgency and importance of legal proceedings.
- Potential Impact Assessment: Such legal actions could negatively affect Regencell's stock price and company reputation, prompting investors to carefully assess their holding risks to make informed investment decisions.
See More
Regencell Bioscience Class Action Reminder for Investors
- Class Action Notification: Robbins LLP reminds all investors who purchased Regencell Bioscience Holdings Limited (NASDAQ:RGC) securities between October 28, 2024, and October 31, 2025, that a class action has been filed to protect investor rights and seek compensation.
- Market Manipulation Allegations: The complaint alleges that Regencell failed to disclose its vulnerability to market manipulation during the class period, exposing investors to significant financial risks and potentially leading to regulatory scrutiny and legal repercussions that could harm the company's reputation.
- Expected Legal Costs: On October 31, 2025, Regencell disclosed in an SEC filing that it received a subpoena from the U.S. Department of Justice due to market volatility, indicating that the company expects to incur significant legal costs and other expenses that may exceed its insurance coverage.
- Stock Price Impact: Following this news, Regencell's ordinary share price fell by $3.09, or 18.56%, closing at $13.56 per share on November 3, 2025, reflecting market uncertainty regarding the company's future and a decline in investor confidence.
See More
Regencell Securities Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, that they must apply to be lead plaintiff by June 23, 2026, to participate in the class action and seek compensation.
- Transparent Fee Structure: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, minimizing financial burdens for participants.
- Firm's Track Record: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its extensive experience and success in this legal domain.
- Case Background: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to significant financial risks and potential regulatory scrutiny, which could adversely affect the company's reputation and financial health.
See More
Regencell Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Regencell in the U.S. District Court for Maryland on behalf of investors who purchased securities between October 28, 2024, and October 31, 2025, indicating significant legal risks for the company.
- Allegations of Misrepresentation: The lawsuit alleges that Regencell made false and misleading statements regarding its business and compliance policies, exposing investors to substantial financial risks and potential regulatory scrutiny.
- Investor Rights Protection: Investors have until June 23, 2026, to apply to be lead plaintiffs in the lawsuit, highlighting the importance of protecting investor rights and potentially influencing future investment decisions.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in shareholder rights, securities, and commercial litigation, underscoring its expertise and influence in safeguarding investor interests.
See More
Regencell Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against Regencell in the U.S. District Court for Maryland on behalf of investors who purchased securities between October 28, 2024, and October 31, 2025, indicating significant legal risks for the company.
- Allegations of Misrepresentation: The lawsuit alleges that Regencell made false and misleading statements regarding its business operations and compliance policies, exposing investors to substantial financial risks and potential regulatory scrutiny.
- Investor Rights Protection: Investors have until June 23, 2026, to apply to be lead plaintiffs, highlighting the importance of protecting investor rights and the potential impact on future investment decisions.
- Legal Consultation Offered: Bragar Eagel & Squire offers free consultations and encourages affected investors to contact attorneys directly to ensure they understand their legal rights and possible remedies.
See More
Regencell Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply as lead plaintiffs by June 23, 2026, to participate in the class action, as those who do not will be ineligible for compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, thereby alleviating financial burdens on investors seeking justice.
- Legal Risks Exposed: The lawsuit alleges that Regencell failed to disclose risks of market manipulation during the class period, exposing investors to significant financial risks and subjecting the company to regulatory scrutiny and potential legal liabilities, which could have long-term reputational impacts.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and experience in handling similar cases.
See More
Faruqi & Faruqi Encourages Regencell Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Regencell Bioscience Holdings Limited related to securities purchased between October 28, 2024, and October 31, 2025, indicating possible legal risks for the company.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing phone numbers and extension for discussing their legal rights, demonstrating a commitment to investor advocacy.
- Class Action Deadline: The firm reminds investors of the June 23, 2026 deadline to seek lead plaintiff status in a federal securities class action filed against Regencell, highlighting the urgency and importance of legal proceedings.
- Potential Impact Assessment: Such legal actions could negatively affect Regencell's stock price and company reputation, prompting investors to carefully assess their holding risks to make informed investment decisions.
See More
Regencell Bioscience Class Action Reminder for Investors
- Class Action Notification: Robbins LLP reminds all investors who purchased Regencell Bioscience Holdings Limited (NASDAQ:RGC) securities between October 28, 2024, and October 31, 2025, that a class action has been filed to protect investor rights and seek compensation.
- Market Manipulation Allegations: The complaint alleges that Regencell failed to disclose its vulnerability to market manipulation during the class period, exposing investors to significant financial risks and potentially leading to regulatory scrutiny and legal repercussions that could harm the company's reputation.
- Expected Legal Costs: On October 31, 2025, Regencell disclosed in an SEC filing that it received a subpoena from the U.S. Department of Justice due to market volatility, indicating that the company expects to incur significant legal costs and other expenses that may exceed its insurance coverage.
- Stock Price Impact: Following this news, Regencell's ordinary share price fell by $3.09, or 18.56%, closing at $13.56 per share on November 3, 2025, reflecting market uncertainty regarding the company's future and a decline in investor confidence.
See More
